Comparing the cost-effectiveness of SGLT2i versus mineralocorticoid antagonists

FHS
June 19, 2023
2:43 pm

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are approved for heart failure with reduced ejection fraction (HFrEF).

Big Drop in Rate of Ipsilateral Breast Cancer After DCIS

The incidence of invasive breast cancer after conservative treatment for ductal carcinoma in situ (DCIS) decreased by more than 50% over the past 30 years,

March 27, 2024

4 Ways to Boost the Patient Experience Using Digital Check-ins

Vijay Verma, VP of Product Strategy at TeleVox Finding a frustrated patient sitting in a waiting room has become familiar. Three and a half years

December 28, 2023

Longer Letermovir Prophylaxis Reduced Risk of Cytomegalovirus Infection After HSCT

Extending the duration of letermovir (Prevymis) prophylaxis following hematopoietic stem cell transplantation (HSCT) was effective in reducing the risk of late clinically significant cytomegalovirus infection,

December 28, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.